Regular HDBuzz readers may recall our September 2024 article examining the long history of pridopidine in Huntington’s ...
In plain language. Written by scientists. ⏱️ 5 min read | Prilenia’s application for European approval of pridopidine was quietly withdrawn 6 months ago, in November 2025, after the EMA had already ...
The one-year report from the TRACK-HD study demonstrates a number of changes in pre-symptomatic HD-mutation carriers ...
On April 30, 2026, uniQure announced that it held a Pre-Submission Meeting with the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) and plans to file a formal application ...
On April 28th 2026, PTC Therapeutics shared new data from the long-term extension of PIVOT-HD, the Phase 2 clinical trial of votoplam, the daily pill designed to lower huntingtin (HTT) protein in ...
Two articles this month took aim at the root cause of HD rather than its downstream consequences. The HTT1a mouse study and the CRISPR study are asking the same fundamental question from different ...
The Total Functional Capacity scale, or TFC, was developed in 1979 by researchers Dr. Stanley Fahn and the late Dr. Ira Shoulson, founder of the Huntington Study Group. They wanted to describe the ...
In plain language. Written by scientists. ⏱️ 10 min read | The Total Functional Capacity score has been used in Huntington’s disease research for decades. Here’s what it measures, what it misses, & ...
The one-year report from the TRACK-HD study demonstrates a number of changes in pre-symptomatic HD-mutation carriers ...
The one-year report from the TRACK-HD study demonstrates a number of changes in pre-symptomatic HD-mutation carriers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results